公开(公告)号：US20170260274A1

公开(公告)日：2017-09-14

申请号：US15509018

申请日：2015-09-07

申请人： Michaela Arndt ,  Jürgen Krauss ,  Stefan Kiesgen

发明人： Michaela Arndt ,  Jürgen Krauss ,  Stefan Kiesgen

IPC分类号： C07K16/28 ,  A61K38/46 ,  C12N7/00 ,  C07K16/30 ,  C12N9/22 ,  C07K7/08

CPC分类号： C07K16/2863 ,  A61K38/465 ,  A61K47/65 ,  A61K47/6889 ,  A61K2039/505 ,  A61K2039/572 ,  C07K7/08 ,  C07K14/08 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/10 ,  C07K2319/21 ,  C07K2319/33 ,  C07K2319/41 ,  C12N7/00 ,  C12N9/22 ,  C12N2770/24122 ,  C12N2770/24132 ,  C12Y301/27 ,  Y02A50/386

摘要： Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1. Further, described is the use of one or more fusogenic sequence(s) derived from dengue virus glycoprotein E for use in delivery of a therapeutic moiety, a detectable moiety, a nucleic acid molecule, preferably an siRNA, a carrier molecule, preferably a nanoparticle, a liposome and a viral vector into the cytoplasm of a cell.